Suppr超能文献

使用韩国国家健康保险索赔数据的横断面研究:帕金森病伴痴呆患者中抗胆碱能药物治疗帕金森病运动症状和乙酰胆碱酯酶抑制剂的同时使用的流行率和模式。

Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson's disease and acetylcholinesterase inhibitors in Parkinson's disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data.

机构信息

College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, 85 Songdogwahak-ro, Incheon, 21983, South Korea.

College of Pharmacy, Chung-Ang University, Seoul, South Korea.

出版信息

BMC Geriatr. 2022 Jul 21;22(1):609. doi: 10.1186/s12877-022-03296-w.

Abstract

BACKGROUND

The concurrent use of anticholinergics and acetylcholinesterase inhibitors (ACHEIs) in Parkinson's disease (PD) patients with dementia should be avoided because the opposing pharmacological actions of both drugs reduce the treatment efficacy. We aimed to investigate the prevalence of the concurrent use of these two types of drugs in Korean patients.

METHODS

In the 2017 Health Insurance Review and Assessment Service-National Aged Patient Sample data, comprising insurance claims records for a 10% random sample of patients aged ≥ 65 years in Korea, "concurrent use" was defined as the overlapping of anticholinergic and ACHEI doses for at least 2 months.

RESULTS

Among 8,845 PD patients with dementia, 847 (9.58%) were co-administered anticholinergics, used to treat the motor symptoms of PD, and ACHEIs for a mean duration of 7.7 months. A total of 286 (33.77% of all co-administered) patients used both drug types concurrently all year. About 80% of concurrent users were prescribed each drug by the same prescriber, indicating that coadministration may not be due to a lack of information sharing between providers. Logistic regression analysis showed that patients mainly treated at clinics (odds ratio (OR), 1.541; 95% confidence interval (CI), 1.158-2.059), hospitals (OR, 2.135; 95% CI, 1.586-2.883), and general hospitals (OR, 1.568; 95% CI, 1.221-2.028) were more likely to be co-prescribed anticholinergics and ACHEIs than those mainly treated at tertiary-care hospitals. PD patients with dementia treated at healthcare organizations located in areas other than the capital city had an approximately 22% higher risk of concurrent use (OR: 1.227, 95% CI: 1.046-1.441).

CONCLUSIONS

The concurrent use of anticholinergics for the motor symptoms of PD and ACHEIs in elderly Korean PD patients with dementia cannot be ignored, and strategies that mitigate potentially inappropriate concurrent drug use are required.

摘要

背景

在患有痴呆症的帕金森病 (PD) 患者中,应避免同时使用抗胆碱能药物和乙酰胆碱酯酶抑制剂 (ACHEIs),因为这两种药物的药理作用相反会降低治疗效果。我们旨在调查这两种药物在韩国患者中同时使用的情况。

方法

在 2017 年健康保险审查和评估服务-国家老年患者样本数据中,包含了韩国年龄在 65 岁及以上的 10%随机抽样患者的保险索赔记录,“同时使用”定义为重叠使用抗胆碱能药物和 ACHEI 剂量至少 2 个月。

结果

在 8845 名患有痴呆症的 PD 患者中,有 847 名 (9.58%) 同时使用了抗胆碱能药物,用于治疗 PD 的运动症状,使用 ACHEI 的平均时间为 7.7 个月。共有 286 名 (所有同时使用药物的患者的 33.77%) 全年同时使用这两种药物。大约 80%的同时使用者由同一位医生开具这两种药物,这表明联合用药可能不是由于提供者之间缺乏信息共享。逻辑回归分析表明,主要在诊所 (比值比 (OR),1.541;95%置信区间 (CI),1.158-2.059)、医院 (OR,2.135;95%CI,1.586-2.883) 和综合医院 (OR,1.568;95%CI,1.221-2.028) 接受治疗的患者更有可能同时开抗胆碱能药物和 ACHEI,而主要在三级保健医院接受治疗的患者则不太可能同时开这两种药物。在首都以外地区医疗机构接受治疗的痴呆症 PD 患者同时使用药物的风险约高 22% (OR:1.227,95%CI:1.046-1.441)。

结论

在韩国患有痴呆症的老年 PD 患者中,不应忽视同时使用抗胆碱能药物治疗 PD 的运动症状和 ACHEI,需要采取策略来减轻潜在的不适当同时用药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b110/9306150/f3b920aed503/12877_2022_3296_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验